Insulet (NASDAQ:PODD) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Insulet from “buy” to “strong-buy”, even as several other analysts recently cut their price targets on the stock.
• Insulet’s latest earnings beat expectations, with EPS of $1.42 on $761.7 million in revenue, and management raised its full-year revenue growth outlook to 21%–23%.
• Despite the positive quarter, the stock has fallen sharply and was trading at $154.16, far below the recent average analyst target of $257.09.

Insulet (NASDAQ:PODD - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday.

Several other equities analysts have also issued reports on PODD. Robert W. Baird lowered their target price on shares of Insulet from $360.00 to $248.00 in a report on Thursday. Sanford C. Bernstein lowered their target price on shares of Insulet from $330.00 to $200.00 and set an "outperform" rating for the company in a report on Thursday. Truist Financial lowered their target price on shares of Insulet from $315.00 to $250.00 and set a "buy" rating for the company in a report on Thursday. Canaccord Genuity Group lowered their target price on shares of Insulet from $435.00 to $249.00 and set a "buy" rating for the company in a report on Thursday. Finally, Royal Bank Of Canada lowered their target price on shares of Insulet from $325.00 to $280.00 and set an "outperform" rating for the company in a report on Thursday. Eighteen analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Insulet has a consensus rating of "Moderate Buy" and an average target price of $257.09.

Insulet Stock Performance

Insulet stock opened at $154.16 on Friday. The company has a current ratio of 2.49, a quick ratio of 2.15 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average of $211.22 and a 200-day moving average of $263.85. The firm has a market cap of $10.68 billion, a P/E ratio of 35.85, a P/E/G ratio of 0.92 and a beta of 1.20. Insulet has a 1-year low of $148.30 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts' consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. During the same period in the prior year, the business posted $1.02 earnings per share. Insulet's revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts expect that Insulet will post 6.46 EPS for the current year.

Insider Buying and Selling at Insulet

In other news, Director Michael R. Minogue purchased 2,030 shares of Insulet stock in a transaction that occurred on Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares of the company's stock, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.36% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insulet

A number of large investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. grew its position in Insulet by 2.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 13,406 shares of the medical instruments supplier's stock worth $2,813,000 after purchasing an additional 274 shares during the period. Earned Wealth Advisors LLC bought a new stake in Insulet in the 1st quarter worth approximately $236,000. Dimensional Fund Advisors LP grew its position in Insulet by 4.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 369,197 shares of the medical instruments supplier's stock worth $77,470,000 after purchasing an additional 14,080 shares during the period. SEB Asset Management AB bought a new stake in Insulet in the 1st quarter worth approximately $24,700,000. Finally, Swiss National Bank grew its position in Insulet by 7.1% in the 1st quarter. Swiss National Bank now owns 206,500 shares of the medical instruments supplier's stock worth $43,332,000 after purchasing an additional 13,600 shares during the period.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s Q1 results beat expectations, with revenue of $761.7 million and EPS of $1.42, and management raised full-year revenue growth guidance to 21%–23%, reinforcing momentum in its Omnipod diabetes platform.
• Positive Sentiment: The company highlighted strong international Omnipod growth and continued expansion of Omnipod 5 into new markets, which suggests the core business remains healthy. Article Title
• Neutral Sentiment: Recent earnings-call coverage and transcript coverage continued to emphasize improved profitability and upbeat management commentary following the Q1 report. Article Title
• Negative Sentiment: Multiple Wall Street firms cut price targets sharply after the earnings report, including Piper Sandler, JPMorgan, Citigroup, Wells Fargo, Stifel, Raymond James, Canaccord Genuity, Leerink, and others, which likely pressured the shares.
• Negative Sentiment: The stock is also trading well below several recent analyst targets, and the cluster of downgrades/target reductions may be signaling concerns about valuation or the pace of future upside despite the earnings beat.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.